Cdk2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
CDK2 encodes cyclin-dependent kinase 2, a serine/threonine kinase that plays central roles in cell cycle regulation, particularly at the G1/S and S phase transitions. CDK2 forms complexes with cyclin E (G1/S) and cyclin A (S phase) to drive cells through S phase and into G2. While CDK2 is essential for cell proliferation, it also has important functions in post-mitotic neurons related to synaptic plasticity, DNA repair, and neuronal survival [1][2].
| Attribute |
Value |
| Gene Symbol |
CDK2 |
| Full Name |
Cyclin-Dependent Kinase 2 |
| Chromosomal Location |
12q13.2 |
| NCBI Gene ID |
1017 |
| Ensembl ID |
ENSG00000145386 |
| UniProt ID |
P24941 |
| Aliases |
CDK2, p33 |
CDK2 spans ~3.5 kb:
- Exons: 9 coding exons
- Transcript: ~1.8 kb mRNA
- Protein: 297 amino acids, ~34 kDa
CDK2 regulates:
- G1/S transition — With cyclin E
- S phase — With cyclin A
- Centrosome cycle — Duplication
- Histone synthesis — S-phase genes
CDK2 in:
- Origin firing — Replication start
- Replication forks — Fork progression
- Repair — Coordinates with repair
In neurons:
- Synaptic plasticity — AMPA receptor trafficking
- DNA repair — Neuronal genome maintenance
- Survival signaling — Can be pro- or anti-death
CDK2 in AD:
- Cell cycle re-entry — Inappropriate activation
- Tau phosphorylation — CDK2 can phosphorylate tau
- Neuronal death — Contributes to degeneration
- Cell cycle activation — Seen in PD
- Dopaminergic loss — CDK2 in neuron death
- Ischemic injury — CDK2 after stroke
- PMID:8340146 — Discovery of CDK2
- PMID:10625657 — CDK2 structure and function
- PMID:11025718 — CDK2 in cell cycle
- PMID:21479819 — CDK2 in neurodegeneration
The study of Cdk2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
CDK2 plays essential roles:
- G1/S transition: Partners with cyclin E
- S phase: Cyclin A/CDK2 drives DNA replication
- G2/M checkpoint: Involved in G2 arrest
- Endoreduplication: Specialized cell cycles
- Cyclin E: G1/S transition (CDK2-cyclin E)
- Cyclin A: S and G2 phases (CDK2-cyclin A)
- Cyclin D: Early G1 (with CDK4/6)
- p21/p27: CDK inhibitors regulate activity
In neurons, CDK2 dysregulation:
- Cell cycle re-entry: Abnormal neuronal cell cycle activity
- DNA damage: Implicated in neuronal death
- Tau phosphorylation: Contributes to neurofibrillary tangles
- Synaptic dysfunction: Alters synaptic plasticity
CDK2 in AD:
- Neuronal cell cycle: Abnormal re-entry in vulnerable neurons
- Amyloid effects: Aβ induces CDK2 activation
- Therapeutic target: CDK inhibitors in development
- Tau pathology: Phosphorylates tau at AD-relevant sites
- Cell death pathways: Contributes to dopaminergic neuron loss
- α-Synuclein: May phosphorylate synuclein
- Mitochondrial dysfunction: Links to PD pathology
Cdk2 knockout mice:
- Viable but sterile: Adult mice survive
- Cell proliferation: Reduced in some tissues
- DNA replication: Impaired S phase
- Compensation: CDK1 can compensate
- Neuronal expression: Cell cycle models in brain
- Alzheimer's models: Crossed with APP/PS1
- Conditional knockouts: Tissue-specific studies
| Drug |
Primary Target |
Development Status |
| Roscovitine |
CDK2/5/7 |
Clinical trials |
| CVT-313 |
CDK2 selective |
Preclinical |
| AT-7519 |
Multi-CDK |
Clinical trials |
- Toxicity: CDK2 inhibition affects proliferation
- CNS penetration: Brain delivery challenges
- Therapeutic window: Balancing efficacy and safety
- Specificity: Achieving selectivity
CDK2 is a central cell cycle kinase with dual roles in normal cell division and pathological neuronal cell cycle re-entry in neurodegeneration. Understanding its regulation in neurons provides therapeutic opportunities for AD and PD.
- Cyclin-dependent kinase 2 activity in Alzheimer's disease brain (2001)
- CDK2 and neuronal cell cycle re-entry in Alzheimer's disease (2005)
- Tau phosphorylation by cyclin-dependent kinases (2004)
- Cell cycle proteins in neurodegenerative diseases (2003)
- Amyloid-beta induced CDK2 activation in neurons (2006)
- CDK2 inhibitors as therapeutic agents for AD (2010)